KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 12-Month High – Should You Buy?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reached a new 52-week high on Wednesday . The company traded as high as $26.75 and last traded at $26.7350, with a volume of 32743624 shares. The stock had previously closed at $19.24.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi has agreed to acquire KalVista for about $1.9 billion, with reported consideration of ~$27.00 per share in cash — a clear strategic exit that explains the strong upside move and creates a near-term certainty of a cash takeover if the deal closes. Italian drugmaker Chiesi to buy KalVista for $1.9 billion
• Positive Sentiment: Market reaction: multiple outlets report KalVista shares surged ~38–39% on the acquisition news and trading volume exploded well above average — investors are pricing in the takeover premium and near-term deal payoff. KalVista stock surges 39% on $1.9 billion Chiesi buyout deal
• Neutral Sentiment: Trading was temporarily halted with the stated reason “News pending” ahead of the announcement, a routine market mechanism that concentrated order flow when the deal broke. (No external link)
• Negative Sentiment: Shareholder legal scrutiny: Ademi LLP has launched an investigation alleging possible breaches of fiduciary duty related to the transaction, signaling potential litigation or shareholder pressure to seek a higher price or concessions. Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
• Negative Sentiment: Additional class‑action investigation: Monteverde & Associates is also probing whether the ~$27 cash offer is fair to shareholders, increasing the chance of litigation or demands for improved terms. The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Citizens Jmp cut their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Thursday, March 26th. HC Wainwright upped their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Needham & Company LLC upped their target price on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Wall Street Zen lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Finally, Stifel Nicolaus upped their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $32.60.

KalVista Pharmaceuticals Stock Performance

The stock has a 50-day simple moving average of $18.01 and a 200-day simple moving average of $15.56. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock has a market cap of $1.37 billion, a PE ratio of -6.76 and a beta of -0.40.

Insider Activity

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 9,550 shares of the business’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $193,101.00. Following the completion of the sale, the chief executive officer owned 462,577 shares of the company’s stock, valued at approximately $9,353,306.94. The trade was a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,686 shares of the business’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the sale, the insider directly owned 142,547 shares of the company’s stock, valued at approximately $2,882,300.34. This trade represents a 1.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 263,969 shares of company stock valued at $4,536,178 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $55,000. Wolverine Asset Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $57,000. Truvestments Capital LLC boosted its position in shares of KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $63,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.